



Telix Pharmaceuticals Limited
ACN 616 620 369
Suite 401, 55 Flemington Road
North Melbourne
Victoria, 3051
Australia

Telix Pharmaceuticals and Merck Group Combination Therapy Collaboration

Melbourne (Australia), Darmstadt (Germany) – 1 Aug 2019. Telix Pharmaceuticals Limited (ASX.TLX, “Telix”) a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on “molecularly-targeted radiation” (MTR) has today disclosed that it has entered into a research collaboration agreement with Merck Healthcare KGaA (“MRK”). This disclosure is made in accordance with Telix’s reporting obligations under ASX Listing Rule 3.1.

Under the terms of the agreement, Telix and MRK will conduct combination studies with several MRK molecules in combination with two (2) of Telix’s MTR therapeutic programs. The agreement provides Telix with access to MRK molecules for use in a mutually agreed research plan to evaluate combination efficacy in models relevant to clinical translation. The agreement includes industry-standard collaborative intellectual property provisions. No Telix intellectual property rights have been granted to MRK at this time. Any follow-on clinical collaboration is subject to the outcomes of the initial research and will be governed by a separate clinical trial agreement to be agreed between the parties.

As the research is commercial-in-confidence, the molecules and oncology focus areas are not disclosed at this time.

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited (Telix) is a global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR). The company is headquartered in Melbourne with international operations in Brussels (EU), Kyoto (JP) and Indianapolis (US). Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com.

Telix Corporate Contact

Dr Christian Behrenbruch
Telix Pharmaceuticals Limited
CEO
Email: chris@telixpharma.com

Telix Investor Relations

Lisa Wilson
In-Site Communications
Tel: +1 212 452 2793
Email: lwilson@insitecony.com

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the “US Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available.